Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 391 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Renal Impaired Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALXN2050 in Participants With Renal Impairment

NCT04623710
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
ALXN2050
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Hialeah, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function

NCT01766154
View directory record Official record
Conditions
Renal Insufficiency
Interventions
Tirofiban
Drug
Lead sponsor
Medicure
Industry
Eligibility
18 Years to 85 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

NCT05412472
View directory record Official record
Conditions
Renal Impairment
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

NCT04179630
View directory record Official record
Conditions
Impaired Renal Function
Interventions
Aldafermin (NGM282)
Biological
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2020 · Synced Sep 8, 2026, 11:52 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)

NCT07348237
View directory record Official record
Conditions
Chronic Kidney Failure, End-Stage Renal Disease, Renal Impairment
Interventions
MK-2828
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
24 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

NCT01235936
View directory record Official record
Conditions
Anemia, Kidney Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Augusta, Georgia • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 2 Interventional

A Pilot Study to Investigate Fenoldopam Usage in the Prevention of Postoperative Renal Dysfunction in Patients at a High Risk for Renal Impairment During Cariopulmonary Bypass for Cardiac Surgery

NCT00467181
View directory record Official record
Conditions
Cardiac Surgery With Cardiopulmonary Bypass
Interventions
Fenoldopam
Drug
Lead sponsor
Summa Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

NCT05404542
View directory record Official record
Conditions
Renal Impairment
Interventions
Tavapadon
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Jacksonville, Florida • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Results available

Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab

NCT02275156
View directory record Official record
Conditions
Hyperlipidemia, Mixed Dyslipidemia
Interventions
Evolocumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

NCT02063204
View directory record Official record
Conditions
Solid Tumours
Interventions
selumetinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 29, 2015 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Results available

Mild, Moderate and Severe Renal Impairment Study

NCT02219516
View directory record Official record
Conditions
Gout
Interventions
RDEA3170
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)

NCT02011490
View directory record Official record
Conditions
Renal Insufficiency, Renal Impairment
Interventions
sugammadex
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)

NCT04303156
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV) Infection
Interventions
Islatravir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901

NCT02975388
View directory record Official record
Conditions
Renal Impairment
Interventions
RO7079901
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
5
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

NCT01558323
View directory record Official record
Conditions
Renal Impairment
Interventions
LCQ908
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996
View directory record Official record
Conditions
Advanced Malignancies
Interventions
parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

NCT01418677
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
E7389
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment

NCT02852239
View directory record Official record
Conditions
Renal Impairment
Interventions
dabrafenib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
3
States / cities
DeBary, Florida • Berlin, New Jersey • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 8, 2026, 11:52 AM EDT
Terminated Phase 1Phase 2 Interventional

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

NCT00150319
View directory record Official record
Conditions
Kidney Failure
Interventions
Vfend®; I.V.
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
New Orleans, Louisiana • Minneapolis, Minnesota • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2008 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lorlatinib Renal Impairment Study

NCT03542305
View directory record Official record
Conditions
Renal Impairment
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Anaheim, California • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Palbociclib (PD-0332991) In Renal Impairment

NCT02085538
View directory record Official record
Conditions
Renal Impairment
Interventions
palbociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
DeLand, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose PK Study of GBT440 in Subjects With Renal Impairment

NCT03161015
View directory record Official record
Conditions
Renal Impairment
Interventions
GBT440
Drug
Lead sponsor
Global Blood Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 21, 2018 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

NCT06318676
View directory record Official record
Conditions
Renal Impairment
Interventions
Mezigdomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 82 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Sep 8, 2026, 11:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

NCT04646889
View directory record Official record
Conditions
Renal Impairment
Interventions
AR882 Single Dose, AR882 Multiple Dose
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 8, 2026, 11:52 AM EDT